Infleqtion, the Boulder, Colorado quantum computing company, completed its merger with Churchill Capital Corp X on February 13, 2026, and will begin trading on the New York Stock Exchange under the ticker INFQ on Monday, February 17. The deal values the company at approximately $1.8 billion with over $550 million in gross proceeds. It is the newest addition to a small but increasingly crowded class of publicly traded quantum companies, arriving at a moment when the sector’s credibility is being tested in real time.
The Infleqtion listing is a neutral atom quantum computing play. Unlike IonQ, which uses trapped ion technology, or IBM, which builds superconducting circuits, Infleqtion’s platform manipulates individual atoms suspended in optical traps using precisely tuned lasers. The approach has theoretical advantages in scalability and parallelism, and recent breakthroughs in neutral atom error correction have strengthened the case for the modality. Infleqtion’s customer list includes NVIDIA, the U.S. Department of Defense, and NASA. The company also advanced to the final stage of the Wellcome Leap Q4Bio Challenge, securing $2 million to validate a quantum enabled biomarker discovery platform for oncology in partnership with the University of Chicago and MIT.
Those credentials read well on paper. The question is whether the public market is willing to pay for them.
The SPAC Problem
The vehicle matters. SPACs, special purpose acquisition companies, have a dismal post merger track record across every sector. According to data compiled by SPAC Research, the median SPAC that completed a merger between 2020 and 2023 was trading below $5 per share within eighteen months of its business combination. Quantum computing is not exempt. IonQ went public via SPAC in 2021. D-Wave went public via SPAC in 2022. Rigetti went public via SPAC in 2022. All three experienced significant post merger declines.
Infleqtion’s SPAC partner, Churchill Capital Corp X, is run by Michael Klein, a serial SPAC sponsor whose prior vehicles include the Churchill Capital Corp IV deal that merged with Lucid Motors in 2021 at a $24 billion valuation. Lucid traded below $2 per share by late 2024. The Klein name carries history, and not the kind that inspires confidence in long term value creation for public shareholders.
The timing compounds the concern. Infleqtion arrives on the NYSE the same week IonQ is trading near 52 week lows, down roughly 10% in five days following the Wolfpack Research short seller report published on February 4, 2026. Wolfpack alleged that 86% of IonQ’s revenue came from Pentagon earmarks that were subsequently canceled. IonQ’s stock has been in freefall ahead of its February 25 earnings call. Meanwhile, Quantinuum, the Honeywell backed quantum company that many consider the sector’s strongest player, filed its confidential S-1 in January 2026 for a traditional IPO targeting a $20 billion plus valuation. Quantinuum projects $2 billion in revenue. IonQ reported $24 million. Infleqtion’s revenue figures have not been disclosed at this scale.
The public quantum market is expanding in headcount while contracting in credibility. More tickers. More scrutiny. Less patience.
The charitable reading is that competition validates the sector. More public quantum companies means more capital, more talent, more engineering hours dedicated to solving the hardest problems in computing. IonQ’s troubles may be company specific, not sector defining. Infleqtion uses a fundamentally different technology. Painting all quantum SPACs with the same brush risks dismissing legitimate differences in approach, team, and execution. That reading deserves space alongside the skepticism.
Claim Versus Capability
Infleqtion has legitimate technology. Its Sqorpius portable quantum sensor has defense applications that go beyond computation into navigation, timing, and threat detection. The company’s neutral atom approach avoids some of the fabrication challenges that plague superconducting systems. And the Q4Bio oncology work, if validated, would represent one of the first genuine quantum advantages in life sciences.
But “if validated” is doing enormous work in that sentence. No neutral atom quantum computer has demonstrated a commercially meaningful quantum advantage over classical systems in production. Infleqtion’s technology is real. Its commercial viability at the stated valuation is unproven. The $1.8 billion price tag is a bet on future capability, not current revenue. That is the same bet the market made on IonQ. The same bet the market made on D-Wave. Both are still trying to prove it was justified.
The question investors need to answer is not whether neutral atom quantum computing works in the lab. It does. The question is whether a $1.8 billion public company is the right vehicle for technology that may need another five to ten years of development before it generates revenue at scale. The broader quantum sector’s answer to that question, as we have examined at length, remains deeply uncertain.
It is worth stating the assumptions embedded in that uncertainty. This analysis assumes the timeline to commercial quantum advantage is long, that SPAC track records are predictive of future SPAC outcomes, and that Infleqtion’s undisclosed revenue numbers are modest relative to the valuation. If any of those assumptions prove wrong, specifically if Infleqtion’s defense sensor contracts generate meaningful near term revenue, or if neutral atom architecture reaches error correction milestones faster than expected, the calculus changes entirely. The Wellcome Leap oncology work with UChicago and MIT, if it produces publishable results, would be among the first peer reviewed demonstrations of quantum advantage in life sciences. That alone could rewrite the valuation case. The smart move is to watch the science, not just the ticker.
The counterargument is that public markets are exactly where quantum companies should be. Private funding rounds create valuation distortions and lock up capital for years. Public listing forces transparency through quarterly reporting, subjects claims to market scrutiny, and gives institutional investors the ability to price risk in real time. Infleqtion going public via SPAC is not a red flag. It is capital efficiency. The company gets funded, investors get liquidity, and the market gets to decide what the technology is worth. Every quantum company that stays private is just delaying that reckoning.
The detail nobody is talking about is the vehicle itself. Quantinuum filed for a traditional IPO with Morgan Stanley and JPMorgan underwriting. Infleqtion went the SPAC route with a serial SPAC sponsor. That is not a neutral choice. Companies that can raise through traditional IPOs do. Companies that cannot, or whose numbers cannot survive the underwriting scrutiny, go SPAC. The technology might be legitimate. The choice of financial vehicle tells you the company’s own bankers had doubts about whether institutional investors would pay this price through the front door. Watch how INFQ trades in its first thirty days. If it follows the SPAC median, it will be below $5 by summer. If it holds, it will be one of the few exceptions that proves the rule. Either way, quantum computing’s public market chapter is being written by financial engineers as much as by physicists, and that should make everyone pay closer attention to the cap table than the qubit count.
What This Means for Everyday People
Quantum computing remains a technology that most people will never interact with directly. But the financial infrastructure being built around it affects everyone. When SPACs take speculative technology public, retail investors often buy the narrative before the revenue exists. The enthusiasm is real. The returns, historically, are not.
If you own index funds, you already have indirect quantum exposure through Google, Microsoft, and IBM. Those companies can absorb quantum R&D costs across diversified businesses. Pure play quantum stocks like INFQ, IONQ, and eventually Quantinuum carry concentrated risk in a sector that has not yet proven it can generate consistent commercial revenue. The gap between scientific capability and investable business remains the central tension in quantum computing. Infleqtion’s public debut does not resolve that tension. It monetizes it.
For inquiries and analysis contact laterstack@proton.me